Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Accured Expenses (2016 - 2025)

Adma Biologics (ADMA) has disclosed Change in Accured Expenses for 13 consecutive years, with $701000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 143.92% year-over-year to $701000.0, compared with a TTM value of $2.3 million through Dec 2025, up 305.33%, and an annual FY2025 reading of $708000.0, up 161.89% over the prior year.
  • Change in Accured Expenses was $701000.0 for Q4 2025 at Adma Biologics, up from -$2.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $8.2 million in Q4 2021 and bottomed at -$6.0 million in Q2 2024.
  • Average Change in Accured Expenses over 5 years is $680000.0, with a median of -$110744.0 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses plummeted 1737.42% in 2021, then soared 4081.48% in 2024.
  • Year by year, Change in Accured Expenses stood at $8.2 million in 2021, then dropped by 4.06% to $7.9 million in 2022, then plummeted by 171.69% to -$5.7 million in 2023, then skyrocketed by 71.82% to -$1.6 million in 2024, then surged by 143.92% to $701000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for ADMA at $701000.0 in Q4 2025, -$2.4 million in Q1 2025, and -$1.6 million in Q4 2024.